Celltrion has launched the Remsima IV liquid formulation in Europe, enhancing its intravenous biosimilar portfolio. The product has secured national tenders in Denmark and Norway, with planned launches in France, the Netherlands, and the Czech Republic this year. The liquid form reduces preparation time and costs by approximately 50%.
This launch strengthens Celltrion’s competitive position in the European biosimilar market by offering a more efficient formulation, potentially accelerating adoption and reducing healthcare costs. It also signals Celltrion’s expanding footprint in key EU countries.
Remsima IV liquid formulation launched in Europe, targeting multiple EU markets.
Secured national tenders in Denmark and Norway, with further launches planned in France, Netherlands, and Czech Republic.
Liquid formulation reduces drug preparation time and costs by approximately 50%.
Secured national tenders in Denmark and Norway, with further launches planned in France, Netherlands, and Czech Republic.
Remsima IV liquid formulation launched in Europe, targeting multiple EU markets.
Sign in to save notes on signals.
Sign In